Growth Metrics

Bionano Genomics (BNGO) Cash from Financing Activities (2017 - 2025)

Bionano Genomics (BNGO) has disclosed Cash from Financing Activities for 9 consecutive years, with $1.6 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities fell 58.79% to $1.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $24.0 million through Dec 2025, up 275.66% year-over-year, with the annual reading at $24.0 million for FY2025, 275.66% up from the prior year.
  • Cash from Financing Activities hit $1.6 million in Q4 2025 for Bionano Genomics, down from $10.1 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $337.5 million in Q1 2021 to a low of -$21.6 million in Q1 2024.
  • Historically, Cash from Financing Activities has averaged $24.2 million across 5 years, with a median of $5.0 million in 2024.
  • Biggest five-year swings in Cash from Financing Activities: soared 212214.29% in 2023 and later crashed 245.46% in 2024.
  • Year by year, Cash from Financing Activities stood at $2.0 million in 2021, then crashed by 92.58% to $146000.0 in 2022, then soared by 46806.85% to $68.5 million in 2023, then tumbled by 94.32% to $3.9 million in 2024, then plummeted by 58.79% to $1.6 million in 2025.
  • Business Quant data shows Cash from Financing Activities for BNGO at $1.6 million in Q4 2025, $10.1 million in Q3 2025, and $1.5 million in Q2 2025.